A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies — Stella

Home/Hematological Malignancies/

View on ClinicalTrials.gov

Recruiting

Back to Hematological Malignancies trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(4 sites)

United States

Research Site, New York, New York

Japan

Aichi Cancer Center Hospital, Nagoya

Research Site, Tokyo

Research Site, Tokyo

Key details

Phase

Early testing / Safety & dosing

Sponsor

Daiichi Sankyo

Enrollment target

~420 participants

Started

January 2026

Primary completion

November 2030

Age range

18 Years and older

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.